110 related articles for article (PubMed ID: 4150813)
1. Relationship of serum triglyceride lowering to changes in hepatic composition induced by different classes of drugs.
Dalton C; Hope WC; Hope HR; Sheppard H
Biochem Pharmacol; 1974 Feb; 23(3):685-96. PubMed ID: 4150813
[No Abstract] [Full Text] [Related]
2. Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate.
Beckett RB; Weiss R; Stitzel RE; Cenedella RJ
Toxicol Appl Pharmacol; 1972 Sep; 23(1):42-53. PubMed ID: 5071041
[No Abstract] [Full Text] [Related]
3. Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat.
Berman JS; Hiley CR; Wilson AC
Br J Pharmacol; 1983 Mar; 78(3):533-41. PubMed ID: 6839062
[TBL] [Abstract][Full Text] [Related]
4. Clofibrate and nafenopin (SU-13437): effects on plasma clearance and tissue distribution of chylomicron triglyceride in the dog.
Cenedella RJ
Lipids; 1972 Oct; 7(10):644-52. PubMed ID: 4635558
[No Abstract] [Full Text] [Related]
5. Effects of S-8527 (1,1-bis4'-(1"-carboxy'1"-methylpropoxy)-phenyl)-cyclohexane), a new hypolipidemic compound, on triglyceride metablolism in rats.
Suzuki K
Biochem Pharmacol; 1975 Jun; 24(11-12):1203-7. PubMed ID: 237511
[No Abstract] [Full Text] [Related]
6. Effect of SaH 42-348, an analog of clofibrate, on lipid metabolism in rats.
Kritchevsky D; Tepper SA
Arzneimittelforschung; 1973 Jun; 23(6):858-9. PubMed ID: 4740771
[No Abstract] [Full Text] [Related]
7. Differential effects of benzodioxane, chroman, and dihydrobenzofuran analogs of clofibrate on various parameters of hepatic drug metabolism.
Lewis NJ; Feller DR; Poochikian GK; Witiak DT
J Med Chem; 1974 Jan; 17(1):41-5. PubMed ID: 4808468
[No Abstract] [Full Text] [Related]
8. Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
Tuchweber B; Salas M
Arch Toxicol; 1978 Dec; 41(3):223-32. PubMed ID: 736793
[TBL] [Abstract][Full Text] [Related]
9. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
Reddy J; Svoboda D; Azarnoff D
Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
[No Abstract] [Full Text] [Related]
10. Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response.
Reddy JK; Azarnoff DL; Svoboda DJ; Prasad JD
J Cell Biol; 1974 May; 61(2):344-58. PubMed ID: 4208071
[TBL] [Abstract][Full Text] [Related]
11. Effect of clofibrate and 1-methyl-4-piperidyl bis (p-chlorophenoxy) acetate (Sandox 42-348) on steroid and drug metabolism by rat liver microsomes.
Salvador RA; Haber S; Atkins C; Gommi BW; Welch RM
Life Sci; 1970 Apr; 9(7):397-407. PubMed ID: 5445848
[No Abstract] [Full Text] [Related]
12. HCG 004, a new highly potent hypolipidaemic drug.
Granzer E; Nahm H
Arzneimittelforschung; 1973 Sep; 23(9):1353-4. PubMed ID: 4801238
[No Abstract] [Full Text] [Related]
13. Drug metabolism and morphologic changes in the liver of nafenopin-treated rats.
Tuchweber B; Kourounakis P; Latour JG
Arch Int Pharmacodyn Ther; 1976 Aug; 222(2):309-21. PubMed ID: 984981
[TBL] [Abstract][Full Text] [Related]
14. Effect of hypolipidemic drugs, nafenopin and clofibrate, on the concentration of ligandin and Z protein in rat liver.
Fleischner G; Meijer DK; Levine WG; Gatmaitan Z; Gluck R; Arias IM
Biochem Biophys Res Commun; 1975 Dec; 67(4):1401-7. PubMed ID: 812503
[No Abstract] [Full Text] [Related]
15. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
Moody DE; Reddy JK
Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):501-10. PubMed ID: 4445568
[No Abstract] [Full Text] [Related]
16. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays.
Warren JR; Simmon VF; Reddy JK
Cancer Res; 1980 Jan; 40(1):36-41. PubMed ID: 6765917
[No Abstract] [Full Text] [Related]
17. Hypolipidemic activity of in vitro inhibitors of hepatic and intestinal sn-glycerol-3-phosphate acyltransferase and phosphatidate phosphohydrolase.
Lamb RG; Wyrick SD; Piantadosi C
Atherosclerosis; 1977 Jun; 27(2):147-54. PubMed ID: 197974
[TBL] [Abstract][Full Text] [Related]
18. Effects of various hypolipidemic drugs on fatty acid composition of liver and serum lipids.
Maier R; Muller K
Adv Exp Med Biol; 1975; 63():349-57. PubMed ID: 1199873
[TBL] [Abstract][Full Text] [Related]
19. [Triglyceride synthesis and oleic acid catabolism by hepatic microsomes and mitochondria in clofibrate or procetofen-treated rats].
Clouet E; Paris R
Reprod Nutr Dev (1980); 1980; 20(3A):637-45. PubMed ID: 7349434
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of clofibrate and halofenate (MK-185) in isolated rat hepatocytes.
Homcy CJ; Margolis S
Atherosclerosis; 1974; 19(3):381-91. PubMed ID: 4828566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
